Journal of Clinical Oncology
Articles in this Issue
Real-world experiences with a multi-cancer detection (MCD) blood test.
10565 Background: Multi-cancer detection (MCD) blood tests hold promise to screen for multiple cancers simultaneously. MCD...
Baseline inflammatory indexes and prognosis for progression-free survival in first-line pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer: A Polish multicenter cohort study.
e13108 Background: Advanced cancer is a systemic disease with inflammation recognized as one of its key hallmarks. Ratios...
Patient-reported performance status as a predictive tool for mortality and supportive care needs in patients with advanced cancer.
1569 Background: Performance status is a key prognostic factor among patients with advanced cancer and can inform the need...
Inpatient burden and outcomes across gastrointestinal cancer subtypes among younger adults in the United States, 2018–2022.
11077 Background: Early-onset gastrointestinal (GI) cancers are increasingly recognized, yet national data describing inpa...
Validation of melanoma immune profile (MIP) to predict RFS in stage II-III melanoma on adjuvant interferon trial (E1697).
e21596 Background: Development of prognostic biomarkers are urgently needed for patients with stage II-III melanoma to str...
Tarlatamab in small cell lung cancer with brain metastases: A real-world experience.
8108 Background: Tarlatamab, a DLL3-directed bispecific T-cell engager, has demonstrated survival benefit in previously tr...
Investigation of the role of IFITM3 and the PI3K/Akt axis in the acute myeloid leukemia tumor microenvironment.
6522 Background: Interferon-induced transmembrane protein 3 (IFITM3) is overexpressed in acute myeloid leukemia (AML) and...
Analysis of <i>BRCA1/2</i> pathogenic variants, homologous recombination deficiency, and MYC amplification in the outcomes of advanced ovarian cancer.
e17585 Background: The association between BRCA1/2 pathogenic variants (PVs) and o...
Ablation success and long-term recurrence with low-dose versus high-dose radioiodine for remnant thyroid ablation in differentiated thyroid carcinoma: A systematic review and meta-analysis of randomized controlled trials.
e18119 Background: Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy. It is typically managed...
Spatial analysis and deep learning integration to enhance tumour classification in total-body PET/CT imaging: A preliminary study.
e17001 Background: Accurate identification of metastases with TNM classification on 68...
Comparative bone health outcomes following tamoxifen and aromatase inhibitor therapy in breast cancer: A large-scale real-world analysis.
e12502 Background: Aromatase inhibitors (AIs) have been associated with increased bone loss and a higher risk of fractures...
Patient-reported quality of life and mood in prolonged responders to immune checkpoint inhibitors for metastatic solid tumors.
e24138 Background: Immune checkpoint inhibitors (ICIs) have transformed metastatic cancer care by enabling prolonged tumor...
Geographic accessibility of recruiting clinical trials for rare and common gastrointestinal malignancies in the United States.
1540 Background: Gastrointestinal (GI) cancers account for substantial cancer mortality, with rare GI malignancies experie...
KITE-753: A phase 2 study of an autologous anti-CD19/CD20 CAR T-cell therapy in CAR-naive patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
TPS7098 Background: CD19-directed CAR T-cell therapy has become the standard of care for R/R LBCL; however, some patients...
An open-label, multicenter study of DPTX3186 to evaluate safety, tolerability, and pharmacokinetics in subjects with known Wnt pathway–activated solid tumors where no other treatments exist.
TPS3169 Background: Constitutive activation of the Wnt/β-catenin pathway drives malignancy in a wide range of cancers, whe...
Phase II study of ABSK061 (selective FGFR2/3 inhibitor) combined with ABSK043 (oral PD-L1 inhibitor) ± CAPOX in advanced FGFR2-positive gastric cancer and gastroesophageal junction cancer (GC/GEJC): Preliminary results from ABSK061-201.
e16036 Background: Aberrant FGFR2 signaling is a validated driver associated with poor prognosis in advanced GC/GEJC. FGFR...
Differential risk patterns of secondary breast cancer in medullary versus papillary thyroid carcinoma survivors: A SEER-based analysis.
10585 Background: Prior studies suggest that thyroid cancer (TC) survivors may have an elevated risk of secondary malignan...
Re-sensitizing PD-1/PD-L1 relapsed/refractory solid tumors: Phase 1a results of IOS-1002, a LILRB1/2 and KIR3DL1 checkpoint inhibitor, in combination with pembrolizumab.
2501 Background: Despite anti-PD-1/PD-L1 therapy success, 60-70% of patients develop progression with limited options (ORR...
Selective bladder-sparing trial with sasanlimab as maintenance treatment based on clinical response to neoadjuvant treatment in molecularly categorized muscle invasive bladder cancer patients: SASAN-SPARING trial.
TPS4644 Background: Muscle-invasive bladder cancer (MIBC) is an aggressive disease with a high risk of progression, for wh...
Safety and 5-year survival following treatment with leronlimab plus physician’s choice combination therapy in patients with metastatic triple-negative breast cancer.
e13109 Background: There is a significant unmet need among patients with PD-L1 low/negative metastatic triple-negative bre...
Molecular differences between early- and later-onset colorectal cancer in a Chilean cohort: A retrospective MSI and NGS-based analysis.
3670 Background: The incidence of early-onset colorectal cancer (EOC) is increasing worldwide; however, molecular data fro...
Identifying optimized dosage for zelenectide pevedotin in locally advanced/metastatic urothelial carcinoma (la/mUC) using quantitative analyses.
4567 Background: Zelenectide pevedotin (zele; BT8009) is a Bicycle Drug Conjugate (BDC) comprising a highly selective bicy...
Comparative outcomes of continuous infusion versus intravenous push followed by infusion 5-fluorouracil in patients with pancreatic and colon cancer: A propensity-matched analysis.
e15735 Background: 5-Fluorouracil (5-FU) is a cornerstone of therapy for gastrointestinal malignancies and is commonly adm...
Real-world phlebotomy (PHL) burden and treatment gaps in US patients with polycythemia vera: A chart review across physician practice settings.
e18588 Background: Guideline-aligned PV management targets hematocrit (HCT) <45% using PHL and/or cytoreductive therapy...
Genetic biomarkers predicting sensitivity to atezolizumab plus bevacizumab in resected hepatocellular carcinoma (HCC): A SNP prediction signature for HCC.
e16014 Background: Current prognostic scoring systems based on clinicopathologic variables are inadequate for identifying...